Heteroaryl compounds useful in the treatment of cognitive disorders

University College Cardiff Consultants Limited 2022. Heteroaryl compounds useful in the treatment of cognitive disorders. WO2022/234271. [Patent].

Preview

PDF - Published Version Download (14MB) | Preview

Abstract

The present invention provides compounds of formula (I), as well as pharmaceutically acceptable salts thereof: wherein X1, X2, X3, R3, Ring A and Ring B are as described herein. The compounds have affinity for α5-subunit-containing GABAA receptors. The invention further provides the manufacture of the compounds of formula (I), pharmaceutical compositions comprising the compounds and their use as medicaments for the treatment of diseases and disorders associated with α5-GABAA receptors, including depression and cognitive impairment, for example, cognitive impairment associated with a psychotic disorders such as schizophrenia.

Item Type:	Patent
Date Type:	Publication
Status:	Published
Schools:	Biosciences
Date of First Compliant Deposit:	3 May 2024
Last Modified:	14 Nov 2024 22:16
URI:	https://orca.cardiff.ac.uk/id/eprint/168702

Actions (repository staff only)

Edit Item